MRK NYSE
Credit Risk of going bust: lower than 79% of companies Debt: 13.4% of company value Bonds: $1.33B held by 448 funds, 49 bp over Treasuries → details ▾
If the stock fell to about $1.48 (down 99%), Merck & Co., Inc. would be worth roughly what it owes.
Total debt $53.91B against a stock market value of $346.91B.
Distance to default 9.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $28.37B (short-term plus half of long-term), stock volatility 29.5%; Altman Z 3.83. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Rahway, NJ 07065
US
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Seidman Christine E | A-Award | 56 | — | 2026-09-30 |
| Karsanbhai Surendral | A-Award | 112 | — | 2026-09-30 |
| Coe Mary Ellen | A-Award | 206 | — | 2026-09-30 |
| Gupta Gaurav K | 0 | — | 2026-09-01 | |
| Gupta Gaurav K | 19,443 | — | 2026-09-01 |